Ironwood Pharmaceuticals, Inc.
(NASDAQ : IRWD)

( )
IRWD PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.48%166.090.7%$1108.87m
PFEPfizer Inc. -0.72%49.750.9%$939.86m
ABBVAbbVie, Inc. -0.22%142.291.9%$831.12m
MRKMerck & Co., Inc. -0.47%90.590.7%$806.25m
LLYEli Lilly & Co. 1.90%313.931.1%$798.53m
BMYBristol-Myers Squibb Co. -1.36%74.541.0%$648.45m
SIGASIGA Technologies, Inc. 5.66%26.150.0%$514.56m
AZNAstraZeneca Plc 0.26%66.811.0%$373.58m
GBTGlobal Blood Therapeutics, Inc. 0.43%67.045.6%$334.64m
ALNYAlnylam Pharmaceuticals, Inc. -1.21%231.018.2%$285.62m
GSKGSK Plc -3.08%34.920.3%$275.20m
HZNPHorizon Therapeutics Plc -3.81%64.905.4%$222.52m
KRTXKaruna Therapeutics, Inc. -1.34%273.710.0%$217.12m
CCXIChemoCentryx, Inc. 0.18%50.812.9%$205.42m
RGENRepligen Corp. 1.74%255.736.7%$190.66m

Company Profile

Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.